
Ustekinumab Plus Prednisone Improves Sustained Remission in Relapsing GCA
Maxime Samson, MD, PhD, discusses phase 2b data showing ustekinumab plus prednisone tripled sustained remission vs prednisone alone in relapsing GCA.
Adding ustekinumab to a standardized prednisone taper more than tripled the rate of sustained remission at 52 weeks in patients with relapsing giant cell arteritis (GCA), according to results from a randomized phase 2b trial presented at
About half of patients relapse as glucocorticoids are tapered, driving up cumulative steroid exposure and related toxicity, Samson noted. Tocilizumab and upadacitinib remain the glucocorticoid-sparing agents with demonstrated efficacy in GCA. Ustekinumab targets the p40 subunit shared by IL-12 and IL-23, blocking both Th1 and Th17 differentiation, the two CD4 T-cell pathways Samson described as acting in synergy to drive vascular inflammation and remodeling.
How Did Ustekinumab Perform in the Phase 2b Trial?
The investigator-initiated, multicenter, open-label superiority trial (NCT03711448) enrolled patients with GCA confirmed by temporal artery biopsy and/or imaging who had relapsed while receiving prednisone 20 mg/day or less.¹,² Participants were randomized 1:1 to subcutaneous ustekinumab 90 mg at weeks 0, 4, 16, and 28 plus prednisone, or prednisone alone. Both arms followed the same taper, starting at 30 mg/day, reaching 5 mg/day at week 25, and ending by week 44.¹
Of 38 randomized patients, 37 were included in the intention-to-treat analysis (ustekinumab, n = 20; control, n = 17).¹ The qualifying relapse was the first for 55% and 59% of patients, respectively. The composite primary endpoint, adjudicated by an independent committee blinded to treatment assignment, required patients to be alive, in sustained remission without relapse, and within 10% of the planned cumulative prednisone dose at week 52.
At week 52, 45% (9/20) of patients receiving ustekinumab met the primary endpoint vs 12% (2/17) of those receiving prednisone alone (absolute difference, 33%; 95% CI, 3%-60%; P = .028).¹ Relapse-free survival also favored ustekinumab (HR, 0.42; 95% CI, 0.18-0.92; P = .026).
When Did the Ustekinumab Treatment Effect Emerge?
Relapse curves overlapped through the first 24 weeks, while higher prednisone doses controlled disease in both arms, then diverged after week 25, Samson explained. Relapse rates with ustekinumab vs control were 20% vs 41% at week 28, 30% vs 65% at week 40 (P = .035), and 50% vs 88% at week 52 (P = .013).¹ Cumulative prednisone doses were similar between groups.
“Taken together with previous studies, it suggests ustekinumab works but works slowly compared to other GC-sparing drugs such as tocilizumab or upadacitinib,” Samson said.
The late relapses, which Samson observed beginning around week 44, also reflect the trial’s dosing window, as ustekinumab was stopped after the week 28 dose. “This study was funded by the French Ministry of Health, so we had a limited amount of money, and we were able to buy treatment until week 28, no more,” he said.
What Was the Safety Profile of Ustekinumab in GCA?
Investigators recorded 10 ustekinumab-related adverse events in six patients, most of them mild.¹ Serious adverse events totaled 10 in the ustekinumab arm and seven in the control arm, though Samson noted French regulations require relapses to be reported as serious adverse events. The only serious event attributed to treatment was Legionella pneumonia in a patient with severe COPD, which resolved, and no deaths occurred in either group.
The trial was small and open-label, and the confidence interval around the primary endpoint was wide. Samson said the findings justify a larger phase 3 trial, ideally with dosing continued beyond week 28. He pointed to a poster from an Irish group led by Molloy and Conway, in which patients received ustekinumab for a longer period with good tolerability and a low rate of relapse after discontinuation.
He also suggested future studies could incorporate cytokine measurement or T-cell subset profiling to determine whether patients with IL-17 and interferon gamma-predominant profiles are the best candidates for the therapy.
References:
Samson M, Bourredjem A, Moulinet T, et al. Ustekinumab plus prednisone versus prednisone alone for refractory giant cell arteritis: a randomized phase IIb open-label trial. Abstract 1896. Presented at: ACR Convergence 2026; November 9, 2026. Accessed November 19, 2026.
https://acrabstracts.org/abstract/ustekinumab-plus-prednisone-versus-prednisone-alone-for-refractory-giant-cell-arteritis-a-randomized-phase-iib-open-label-trial/ Ustekinumab in giant cell arteritis. ClinicalTrials.gov identifier: NCT03711448. Accessed November 19, 2026.
https://clinicaltrials.gov/study/NCT03711448
Related to this article







